Navigation Links
Study identifies protein to repair damaged brain tissue in MS
Date:2/7/2014

Vittorio Gallo, PhD, Director of the Center for Neuroscience Research at Children's National Health System, and other researchers have found a "potentially novel therapeutic target" to reduce the rate of deterioration and to promote growth of brain cells damaged by multiple sclerosis (MS). Current therapies can be effective in patients with relapsing MS, but have little impact in promoting tissue growth.

The brain produces new cells to repair the damage from MS years after symptoms appear. However, in most cases the cells are unable to complete the repair, as unknown factors limit this process. In MS patients, brain inflammation in random patches, or lesions, leads to destruction of myelin, the fatty covering that insulates nerve cell fibers called axons in the brain, and aids in transmission of signals to other neurons.

In yesterday's publication of Neuron, Gallo, who also is a professor of pediatrics at the George Washington University School of Medicine and Health Sciences (SMHS), reported identifying a small protein that can be targeted to promote repair of damaged tissue, with therapeutic potential. The molecule, Endothelin-1 (ET-1), is shown to inhibit repair of myelin. Myelin damage is a hallmark characteristic of MS. The study demonstrates that blocking ET-1 pharmacologically or using a genetic approach could promote myelin repair.

Repair of damaged MS plaques is carried out by endogenous oliogdendrocytle progenitor cells (OPCs) in a process called remyelination. Current MS therapy can be effective in patients with relapsing and remitting MS, but "have little impact in promoting remyelination in tissue," Gallo said. Several studies have shown that OPCs fail to differentiate in chronic MS lesions.

Targeting ET-1 is a process that involves identifying signals in cells that could promote lesion repair. "We demonstrate that ET-1 drastically reduces the rate of remyelination," Gallo said. As such, ET-1 is "potentially a therapeutic target to promote lesion repair in deymyelinated tissue." It could play a "crucial role in preventing normal myelination in MS and in other demyelinating diseases," Gallo said.


'/>"/>
Contact: Joe Cantlupe
jcantlupe@childrensnational.org
202-476-4500
Children's National Medical Center
Source:Eurekalert

Related medicine news :

1. Ice ages arctic tundra lush with wildflowers for woolly mammoths, study finds
2. Director of Womens Guild Lung Institute awarded grant to study treatment for lung disease
3. Columbia study finds hospitals dont follow infection prevention rules
4. Penn study reveals genetics impact risk of early menopause among some female smokers
5. New study finds feeling in control can help you live longer
6. Population Council launches study testing interventions to improve girls lives in Kenya
7. Study finds dramatic rise in skin cancer among middle-aged adults
8. New study shows core factors and strategies to turn primary care practices into PCMHs
9. Study finds high Rx burden for bipolar patients
10. Using susceptibility-weighted imaging to study concussion in college ice hockey players
11. New study explores contributors to excess infant mortality in the US South
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... 12, 2017 , ... First Healthcare Compliance (FHC), an industry ... a range of technology and learning solutions at the 68th Annual American Healthcare ... be held October 14–18, 2017 at the Mandalay Bay Resort in Las Vegas, ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... ... Asante, a nationally recognized health system in southern Oregon, ... health joint venture through an agreement, effective October 1, 2017, to create AccentCare ... company with Asante, delivering clinically integrated care, for the past eight years. This ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... for ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards ... recognizes editorial and design excellence across a range of sectors. This year’s program included ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned ... Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite Wellness ... on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the Henry ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... YORK , Sept. 27, 2017  DarioHealth Corp. (NASDAQ: DRIO), a ... today announced that its MyDario product is expected to appear on The ... when The Dr. Oz Show airs in your area: http://www.doctoroz.com/page/where-watch-dr-oz-show ... The nine-time Emmy award-winning, The Dr. Oz ... The ...
(Date:9/23/2017)... 2017 Janssen Biotech, Inc. (Janssen) announced today ... the U.S. Food and Drug Administration (FDA) for the ... the treatment of moderately to severely active rheumatoid arthritis ... are needed to further evaluate the safety of sirukumab ... "We are ...
(Date:9/19/2017)... -- HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy ... team developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D ...
Breaking Medicine Technology: